InNexus Biotechnology Inc. TSX.V IXS

Tags: Jeff, Morhet, TSX.V, IXS, Life, Sciences, monoclonal, antibodies, Dynamic, cross, linking, technology, antigen, binding, pharmaceutical, biotechnology, cancer, lymphoma, InNexus, Biotechnology, Inc, video, public, company, companies

Jeff Morhet, President & CEO

InNexus Biotechnology Inc. is a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking technology (DXL™) improving the potency of existing antibody products while opening new markets and disease applications.

Sector: Life Sciences
Main Exchange: TSX.V IXS
Secondary Listing: N/A

Added: 30th July 2008
Views: 266